巅峰国际

Be the most trusted biotech company

2025-06-13

Expanding Southeast Asian Presence: Serplulimab Approved in Singapore and Malaysia
2025-06-10

First Subject Dosed for a Phase 2 MRCT of Henlius’ PD-L1-Targeting ADC HLX43 for the Treatment of NSCLC
2025-06-09

Henlius Showcases Global Innovation Momentum at Jefferies Global Healthcare Conference 2025
2025-06-06

Henlius Hosts Global Oncologists Reception During ASCO 2025, Highlighting Innovation and Collaboration
2025-06-04

Updated results and biomarker analysis from the Pivotal Clinical Trial ASTRUM-005 of Serplulimab Published on Cancer Communications
2025-06-03

Results from the Phase 1 Clinical Trial of Henlius PD-L1 ADC HLX43 Released at 2025 ASCO Annual Meeting
2025-06-03

Henlius Unveils Updated Phase 2 Results and Phase 3 Trial Design for Anti-HER2 mAb HLX22 in First-Line HER2+ Gastric Cancer
2025-06-01

Latest Results of Serplulimab in Lung and Gastrointestinal Cancer Released at ASCO 2025
2025-05-26

Henlius Receives Orphan Drug Designation for Its Innovative Anti-HER2 mAb HLX22 in the European Union for Gastric Cancer